Attention deficit hyperactivity disorder (ADHD). Attention-deficit hyperactivity disorders
Conditions
Interventions
Intervention 1: Control Group (Atomoxetine): Participants in this group will receive atomoxetine. Treatment starts at 0.5 mg/kg/day and will be increased every three weeks if tolerated. The maximum al
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Age between 6 and 12 years ADHD diagnosis based on DSM-5 criteria
Exclusion criteria
Exclusion criteria: Having Intellectual Disbility or serious illnesses (such as serious heart disease, thyroid disease, liver disease, and kidney disease) Major psychiatric disorders (excluding problems related to ADHD) Previous treatment for ADHD (such as stimulant or antipsychotic medications) within two weeks prior to the start of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of ADHD symptoms. Timepoint: Before treatment and at weeks 0, 3, and 6 after treatment. Method of measurement: Changes in the average score of the Conners Parent Rating Scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in children's anxiety levels. Timepoint: before treatment and at weeks 0, 3, and 6 after treatment. Method of measurement: Determining changes in the mean score of the Revised Children Manifest Anxiety Scale.;Children's depression. Timepoint: before treatment and at weeks 0, 3, and 6 after treatment. Method of measurement: Determining changes in the mean score of the Children's Depression Inventory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Shahrivar
Tehran University of Medical Sciences
Outcome results
None listed